Systematic pan-cancer analysis of mutation-treatment interactions using large real-world clinicogenomics data

被引:23
作者
Liu, Ruishan [1 ,2 ]
Rizzo, Shemra [3 ]
Waliany, Sarah [4 ]
Garmhausen, Marius Rene [3 ]
Pal, Navdeep [3 ]
Huang, Zhi
Chaudhary, Nayan [3 ]
Wang, Lisa [3 ]
Harbron, Chris [5 ]
Neal, Joel [4 ]
Copping, Ryan [3 ]
Zou, James [1 ,2 ]
机构
[1] Stanford Univ, Dept Elect Engn, Stanford, CA 94305 USA
[2] Stanford Univ, Dept Biomed Data Sci, Stanford, CA 94305 USA
[3] Genentech Inc, San Francisco, CA USA
[4] Stanford Univ, Sch Med, Stanford, CA USA
[5] Roche Pharmaceut, Welwyn Garden City, Herts, England
基金
美国国家科学基金会;
关键词
METASTATIC UROTHELIAL CARCINOMA; RB-PATHWAY DISRUPTION; NEOADJUVANT CHEMOTHERAPY; TP53; MUTATIONS; OPEN-LABEL; ATEZOLIZUMAB; MULTICENTER; PROGNOSIS; ASSOCIATION; EXPRESSION;
D O I
10.1038/s41591-022-01873-5
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Quantifying the effectiveness of different cancer therapies in patients with specific tumor mutations is critical for improving patient outcomes and advancing precision medicine. Here we perform a large-scale computational analysis of 40,903 US patients with cancer who have detailed mutation profiles, treatment sequences and outcomes derived from electronic health records. We systematically identify 458 mutations that predict the survival of patients on specific immunotherapies, chemotherapy agents or targeted therapies across eight common cancer types. We further characterize mutation-mutation interactions that impact the outcomes of targeted therapies. This work demonstrates how computational analysis of large real-world data generates insights, hypotheses and resources to enable precision oncology. A large-scale computational analysis of over 40,000 patients with cancer who have detailed mutation profiles, treatment sequences and outcomes derived from electronic health records provides insights into a rich resource that will help to enable precision oncology.
引用
收藏
页码:1656 / +
页数:18
相关论文
共 53 条
  • [11] Development and Validation of a High-Quality Composite Real-World Mortality Endpoint
    Curtis, Melissa D.
    Griffith, Sandra D.
    Tucker, Melisa
    Taylor, Michael D.
    Capra, William B.
    Carrigan, Gillis
    Holzman, Ben
    Torres, Aracelis Z.
    You, Paul
    Arnieri, Brandon
    Abernethy, Amy P.
    [J]. HEALTH SERVICES RESEARCH, 2018, 53 (06) : 4460 - 4476
  • [12] Electronic medical records can be used to emulate target trials of sustained treatment strategies
    Danaei, Goodarz
    Garcia Rodriguez, Luis Alberto
    Fernandez Cantero, Oscar
    Logan, Roger W.
    Hernan, Miguel A.
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2018, 96 : 12 - 22
  • [13] Reduced NF1 Expression Confers Resistance to EGFR Inhibition in Lung Cancer
    de Bruin, Elza C.
    Cowell, Catherine
    Warne, Patricia H.
    Jiang, Ming
    Saunders, Rebecca E.
    Melnick, Mary Ann
    Gettinger, Scott
    Walther, Zenta
    Wurtz, Anna
    Heynen, Guus J.
    Heideman, Danielle A. M.
    Gomez-Roman, Javier
    Garcia-Castano, Almudena
    Gong, Yixuan
    Ladanyi, Marc
    Varmus, Harold
    Bernards, Rene
    Smit, Egbert F.
    Politi, Katerina
    Downward, Julian
    [J]. CANCER DISCOVERY, 2014, 4 (05) : 606 - 619
  • [14] Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
    Dong, Zhong-Yi
    Zhong, Wen-Zhao
    Zhang, Xu-Chao
    Su, Jian
    Xie, Zhi
    Liu, Si-Yang
    Tu, Hai-Yan
    Chen, Hua-Jun
    Sun, Yue-Li
    Zhou, Qing
    Yang, Jin-Ji
    Yang, Xue-Ning
    Lin, Jia-Xin
    Yan, Hong-Hong
    Zhai, Hao-Ran
    Yan, Li-Xu
    Liao, Ri-Qiang
    Wu, Si-Pei
    Wu, Yi-Long
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (12) : 3012 - 3024
  • [15] Mutations in GRIN2A and GRIN2B encoding regulatory subunits of NMDA receptors cause variable neurodevelopmental phenotypes
    Endele, Sabine
    Rosenberger, Georg
    Geider, Kirsten
    Popp, Bernt
    Tamer, Ceyhun
    Stefanova, Irina
    Milh, Mathieu
    Kortuem, Fanny
    Fritsch, Angela
    Pientka, Friederike K.
    Hellenbroich, Yorck
    Kalscheuer, Vera M.
    Kohlhase, Juergen
    Moog, Ute
    Rappold, Gudrun
    Rauch, Anita
    Ropers, Hans-Hilger
    von Spiczak, Sarah
    Toennies, Holger
    Villeneuve, Nathalie
    Villard, Laurent
    Zabel, Bernhard
    Zenker, Martin
    Laube, Bodo
    Reis, Andre
    Wieczorek, Dagmar
    Van Maldergem, Lionel
    Kutsche, Kerstin
    [J]. NATURE GENETICS, 2010, 42 (11) : 1021 - U153
  • [16] BRAF Mutation in Colorectal Cancer: An Enigmatic Target
    Eng, Cathy
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (04) : 259 - +
  • [17] RB-pathway disruption in breast cancer Differential association with disease subtypes, disease-specific prognosis and therapeutic response
    Ertel, Adam
    Dean, Jeffry L.
    Rui, Hallgeir
    Liu, Chengbao
    Witkiewicz, Agnes K.
    Knudsen, Karen E.
    Knudsen, Erik S.
    [J]. CELL CYCLE, 2010, 9 (20) : 4153 - 4163
  • [18] Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
    Frampton, Garrett M.
    Fichtenholtz, Alex
    Otto, Geoff A.
    Wang, Kai
    Downing, Sean R.
    He, Jie
    Schnall-Levin, Michael
    White, Jared
    Sanford, Eric M.
    An, Peter
    Sun, James
    Juhn, Frank
    Brennan, Kristina
    Iwanik, Kiel
    Maillet, Ashley
    Buell, Jamie
    White, Emily
    Zhao, Mandy
    Balasubramanian, Sohail
    Terzic, Selmira
    Richards, Tina
    Banning, Vera
    Garcia, Lazaro
    Mahoney, Kristen
    Zwirko, Zac
    Donahue, Amy
    Beltran, Himisha
    Mosquera, Juan Miguel
    Rubin, Mark A.
    Dogan, Snjezana
    Hedvat, Cyrus V.
    Berger, Michael F.
    Pusztai, Lajos
    Lechner, Matthias
    Boshoff, Chris
    Jarosz, Mirna
    Vietz, Christine
    Parker, Alex
    Miller, Vincent A.
    Ross, Jeffrey S.
    Curran, John
    Cronin, Maureen T.
    Stephens, Philip J.
    Lipson, Doron
    Yelensky, Roman
    [J]. NATURE BIOTECHNOLOGY, 2013, 31 (11) : 1023 - +
  • [19] Precision Oncology: An Overview
    Garraway, Levi A.
    Verweij, Jaap
    Ballman, Karla V.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15) : 1803 - 1805
  • [20] Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer
    Guibert, Nicolas
    Jones, Greg
    Beeler, John F.
    Plagnol, Vincent
    Morris, Clive
    Mourlanette, Jean
    Delaunay, Myriam
    Keller, Laura
    Rouquette, Isabelle
    Favre, Gilles
    Pradines, Anne
    Mazieres, Julien
    [J]. LUNG CANCER, 2019, 137 : 1 - 6